CME Information
Learning Objectives
At the conclusion of the program, participants will be better able to:
- Interpret principles of anatomy and pathophysiology for a variety of clinical conditions in order to assess the need for botulinum neurotoxin treatment
- Perform comprehensive and individualized patient assessments in order to identify appropriate patients for botulinum neurotoxin therapy and determine realistic treatment goals
- Understand the different botulinum neurotoxin formulations, in order to administer a specific therapeutic regimen appropriate for each individual patient
- Demonstrate procedures and techniques for botulinum neurotoxin injections including the use of localization and guidance modalities, in order to assure optimal product placement and therapeutic outcomes
- Facilitate interaction and improve communication among members of the clinical care team and with the patient in order to achieve treatment goals
Target Audience
The preceptorship program is designed for clinicians in the fields of neurology, physical medicine and rehabilitation, and other specialties who wish to improve and/or expand their knowledge and skills in the management of patients with clinical conditions for which botulinum neurotoxin is an evidence-based treatment option.
Conflict of Interest Statement
The “Policy on Identification, Mitigation and Disclosure of Relevant Financial Relationships” of Albert Einstein College of Medicine-Montefiore Medical Center requires that faculty participating in any CME/CE activity disclose to the audience any relevant relationships with an ineligible company or companies.* Any presenter whose disclosed relationships prove to create a conflict of interest, with regard to his or her contribution to the activity, will not be permitted to present.
Albert Einstein College of Medicine-Montefiore Medical Center also requires that faculty participating in any CME/CE activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device, not yet approved in the United States. All financial relationships listed for individuals have been mitigated.
*The Accreditation Council for Continuing Medical Education (ACCME) defines an ineligible company as those whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.
Planning Committee and Disclosures
Katharine Alter, MD
Medical Director
Functional and Applied Biomechanics Section
Senior Clinician
National Institutes of Health
Bethesda, Maryland
Katharine Alter, MD, has indicated that she has no relevant financial relationships with commercial interests to disclose in the last 24 months.
Laxman Bahroo, DO
Professor and Director of the Residency Program
Department of Neurology
Medstar Georgetown University Hospital
Washington, DC
Laxman Bahroo, DO, received consulting fees for serving on the advisory board from Acadia, Amneal, Ipsen, Neurocrine, Revance, and Supernus; received honoraria for serving on the speakers’ bureau from Acadia, Amneal, Ipsen, Kyowa Kirin, Merz, Neurocrine, Sunovion, Supernus, and Teva.
David Charles, MD
Professor and Vice-Chair of Neurology
Vanderbilt University Medical Center
Nashville, Tennessee
David Charles, MD, received grants or research support from Aeon, AskBio, BlueRock, Bukwang, Inhibikase, Ipsen, Merz, Novartis, Pharma Two B, and Supernus; received consulting fees from Abbott, AbbVie, Amneal, IOTA, Ipsen, Revance, Newronika,and Supernus.
Cindy Ivanhoe, MD
Clinical Professor
Physical Medicine and Rehabilitation
McGovern Medical School
The University of Texas Health Science Center at Houston
Baylor College of Medicine
Houston, Texas
Cindy Ivanhoe, MD, received grants or research support from Ipsen; received consulting fees for serving as a member of a speakers’ bureau from Merz; and received consulting fees from Revance.
David Simpson, MD
Professor of Neurology
Director
Clinical Neurophysiology Labs and Neuromuscular Division
Icahn School of Medicine at Mount Sinai
New York, New York
David Simpson, MD, received honoraria from AbbVie, Ipsen, and Merz.
This CME activity will discuss off-label uses of botulinum neurotoxin.
CME Program Reviewer
Victor B. Hatcher, PhD
Professor of Biochemistry and Medicine
Associate Dean
Albert Einstein College of Medicine
Research Director
Montefiore Medical Center
Bronx, New York
Victor B. Hatcher, PhD, has indicated no relevant financial relationships with commercial interests to disclose in the last 24 months.
Planner
Carol Tucker, MSc
Senior Vice President, Scientific Affairs
Scientiae, LLC
New York, New York
Carol Tucker, MSc, has indicated no relevant financial relationships with commercial interests to disclose.
Americans With Disabilities Act
Albert Einstein College of Medicine-Montefiore Medical Center and the International Neurotoxin Association (INA) fully intend to comply with the legal requirements of the Americans with Disabilities Act. If any participant in this activity is in need of special accommodations, please contact the INA at least two weeks prior to the activity at preceptorship@neurotoxins.org.
Accreditation Statement
In support of improving patient care, this activity has been planned and implemented by Albert Einstein College of Medicine-Montefiore Medical Center and the International Neurotoxin Association. Albert Einstein College of Medicine-Montefiore Medical Center is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Credit Designation Statement
Albert Einstein College of Medicine-Montefiore Medical Center designates this live activity for a maximum of 5.0 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in this activity.
Providership Statement
This activity is jointly provided by Albert Einstein College of Medicine-Montefiore Medical Center and the International Neurotoxin Association (INA).
Supported by an educational grant and in-kind contribution of disposable and biological supplies from AbbVie, an educational grant from Ipsen, and an educational grant and in-kind contribution of product from Merz.
